Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Zelboraf (vemurafenib) is a kinase inhibitor approved by the FDA for the treatment of unresectable or metastatic melanoma with a BRAF V600E mutation, and for Erdheim-Chester disease with a BRAF V600 mutation.
Zelboraf selectively inhibits mutated BRAF kinase, blocking abnormal signaling in the MAPK pathway that drives tumor growth in cancers carrying the BRAF V600E mutation.
Zelboraf is intended for patients with unresectable or metastatic melanoma confirmed to carry a BRAF V600E mutation through an approved test, as well as patients with the rare histiocytic disorder Erdheim-Chester disease carrying a BRAF V600 mutation.
The recommended dose of Zelboraf is 960 mg (four 240 mg tablets) taken orally twice daily, approximately 12 hours apart, with or without food, continued until disease progression or unacceptable toxicity.
Zelboraf does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
New primary cutaneous and non-cutaneous malignancies, including cutaneous squamous cell carcinoma, have been reported. Regular skin examinations are recommended before and during treatment.
BRAF mutation status should be confirmed before starting treatment, as Zelboraf can promote tumor growth in melanomas without a BRAF V600 mutation.
Zelboraf can prolong the QT interval; ECG monitoring is recommended, particularly in patients with risk factors. Liver enzyme elevations have also been reported, requiring periodic monitoring.
Severe photosensitivity reactions can occur; patients should use sun protection. Dupuytren's contracture and plantar fascial fibromatosis have also been reported with prolonged use.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Zelboraf is manufactured and marketed by Genentech USA, Inc., a member of the Roche Group. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating oncologist confirming diagnosis and BRAF V600 mutation testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for BRAF V600E-mutated melanoma and Erdheim-Chester disease, Zelboraf is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Zelboraf directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Zelboraf should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, in its original container with the lid tightly closed, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Zelboraf through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Zelboraf access.
Delhi's major hospitals assist patients with prescription support and documentation for Zelboraf.
Bangalore's specialist network offers access coordination for eligible BRAF-mutated melanoma patients seeking Zelboraf.
Chennai-based oncology specialists coordinate Zelboraf access alongside comprehensive melanoma care.
Hyderabad's care institutions support patients pursuing Zelboraf therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Zelboraf.
Pune-based specialists assist with prescription support and Zelboraf treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Zelboraf.
Kochi's specialist units assist patients with the documentation needed for Zelboraf access.
Chandigarh's care centers support Zelboraf treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Zelboraf access process.
Lucknow-based centers assist patients pursuing Zelboraf therapy.
Bhubaneswar's institutions support access to Zelboraf for eligible patients.
Guwahati's specialists help coordinate Zelboraf access for patients across the Northeast.
Patients in other cities across India can also access Zelboraf through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
